Proamin Injection

Adult administration

For peripheral venous administration, slowly infuse 200–400 mL intravenously per dose. The infusion rate should be based on 200 mL over 120 minutes (approximately 25 drops per minute), with approximately 10 g of amino acid intake being ideal for the body every hour, and it should be infused slowly for pediatric, elderly, or critically ill patients. For central venous administration, continuously infuse 400–800 mL per day according to high-calorie fluid methods. Adjust the speed and amount of infusion for pediatric, elderly patients, or those with high protein demand such as burn patients.

Child administration

For peripheral venous administration, pediatric patients should receive the infusion slowly. For central venous administration, pediatric dosage and infusion rates should be adjusted appropriately.

This medicine must be used strictly under the guidance of a physician, and should not be taken or discontinued on one's own. It should not be administered to patients with hepatic coma symptoms or those at risk of hepatic coma. Additionally, patients with severely impaired kidney function or elevated nitrogen levels in the blood should also avoid using this medication. Patients with issues in nitrogen metabolism, severe heart failure, pulmonary edema, very low or absent urine output, and those with high sodium or chloride levels or alkalosis in the blood should also not be administered this medicine. Patients with a history of myocardial infarction or those currently experiencing myocardial infarction should also avoid this medication. This medicine should be used cautiously in certain situations. For example, patients with severe acidosis, congestive heart failure, abnormal sodium or potassium levels, or impaired liver or kidney function should be carefully monitored when using this medicine. Moreover, one of the ingredients, sodium pyruvate, can cause allergic reactions and may trigger asthma attacks, especially in asthma patients, so caution is warranted. This medication may rarely cause hypersensitivity reactions manifesting as skin rashes, and occasionally gastrointestinal symptoms such as nausea or vomiting may occur. Cardiac symptoms may include discomfort in the chest, palpitations, tachycardia, and elevated blood pressure. Rapidly administering a high volume of this medicine can lead to metabolic acidosis due to blood acidification. Additionally, symptoms such as chills, fever, headache, respiratory distress, shock, bronchospasm, and urinary tract spasms may occur, so any abnormal symptoms should be reported to medical professionals immediately. This medication can cause metabolic complications, including metabolic acidosis, decreased phosphate in the blood, alkalosis, elevated blood sugar, diabetes, dehydration, rebound hypoglycemia, liver dysfunction, vitamin imbalances, and electrolyte imbalances. Patients with poor liver or kidney function may experience elevated blood urea nitrogen levels, and patients with liver dysfunction may be at risk of amino acid imbalance and altered consciousness. When this medication is used in large volumes or in conjunction with other electrolyte-containing fluids, care must be taken to monitor electrolyte balance, as overdose could lead to blood becoming alkaline. Patients with a history of kidney, pulmonary, or cardiac diseases require careful administration to avoid fluid overload issues. Diabetic patients should regularly monitor blood sugar levels while using this medication. Caution is advised when this medication is used alongside certain antibiotics, such as tetracycline, as it may reduce protein-sparing effects. The safety of this medication during pregnancy has not been fully established, so it should only be used during pregnancy when the benefits outweigh the risks. For pediatric patients, maintaining lower concentrations is advisable due to potentially immature liver function, and particularly in infants, ammonia levels should be regularly monitored. Elderly patients may have diminished physical function; therefore, the administration speed should be slowed and dosing adjusted appropriately. This medicine contains electrolytes, and rapid administration may lead to side effects such as chills or vomiting, thus it should be slowly infused intravenously. The infusion fluids should be warmed to body temperature and strict aseptic conditions should be maintained during preparation and administration, confirming that the solution is clear and transparent before use. Do not use if there are residuals or discolorations, or leaks, and use as soon as possible after mixing, within 24 hours if refrigerated. During storage, do not open the packaging and do not use if the protective film over the rubber cap is damaged. Exact dosing should be administered according to the markings on the container.

Serious side effects

• Respiratory distress
• respiratory arrest
• shock
• bronchospasm
• liver failure
• kidney failure
• severe headache
• altered consciousness.

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• tachycardia
• elevated blood pressure
• chills
• fever
• headache

This medicine should be stored in a sealed container to avoid exposure to air, and it is safest to store it at room temperature between 1 to 30 degrees Celsius. Storing it this way helps maintain the efficacy of the medication and prevent deterioration.

Appearance

Colorless, transparent liquid contained in a colorless, transparent vial injection.

Package unit

200 mL/bottle, 250 mL/bottle, 500 mL/bottle